Vancouver’s Aspect Biosystems today announced a US $20 million Series A financing round led by Radical Ventures with participation from investors Pangaea Ventures, Pallasite Ventures, and Rhino Ventures.
Aspect is a biotechnology company pioneering microfluidic 3D bioprinting of human tissues and will use this capital to advance multiple tissue therapeutic programs, expand its technology platform capabilities, and grow its world-leading team.
“We are thrilled to close this important institutional financing round with a group of world-class investors who believe in our bold vision,” said Tamer Mohamed, CEO, Aspect Biosystems.
“This funding speaks to the power of our technology and strategy in addressing multiple applications in therapeutic discovery and regenerative medicine, and will allow us to accelerate internal innovation and expand our global partnerships. With our technology platform, interdisciplinary team of scientists and engineers, and leading collaborators, we are developing a new wave of solutions that have the potential to transform how we heal injury and disease.”
Aspect’s broadly applicable technology platform enables the creation of living human tissues with unprecedented control, flexibility, and precision.
In addition to Aspect’s internal tissue therapeutic programs for regenerative medicine, the Company works with its global partners to create high-value solutions that will transform medical research and clinical practice.